Author(s):
Mohit Sunil Pawar, Hetakshi Vilas Patil, Harshada Kailas Patil, Sejal Tukaram Patel, Amitkumar R. Dhankani, Mansi A. Dhankani, Sunil P. Pawar
Email(s):
mohitpawar477@gmail.com
DOI:
10.52711/2231-5675.2025.00036 
Address:
Mohit Sunil Pawar*, Hetakshi Vilas Patil, Harshada Kailas Patil, Sejal Tukaram Patel, Amitkumar R. Dhankani, Mansi A. Dhankani, Sunil P. Pawar
P.S.G.V.P Mandal’s College of Pharmacy Shahada, Dist- Nandurbar - 425409 Maharashtra – India.
*Corresponding Author
Published In:
Volume - 15,
Issue - 3,
Year - 2024
ABSTRACT:
Chronic constipation is a common gastrointestinal disorder with complex pathophysiology and diverse treatment options. Prucalopride, a highly selective serotonin 5-HT4 receptor agonist, has emerged as a novel enterokinetic therapy for managing chronic idiopathic constipation (CIC). Unlike earlier serotonergic prokinetic agents, prucalopride exhibits high receptor selectivity, minimizing interactions with other receptor systems and reducing the risk of adverse effects. Its mechanism of action involves enhancing colonic motility by stimulating acetylcholine release from enteric neurons, thereby facilitating bowel movements. Various analytical methods, including UV spectrophotometry, high-performance liquid chromatography (HPLC), and ultra-high-performance liquid chromatography (UHPLC), have been employed for its quantification in pharmaceutical and biological matrices. The development and validation of these methods ensure accurate drug estimation, supporting its clinical and pharmaceutical applications. This review provides a comprehensive overview of various analytical techniques employed for prucalopride analysis, including ultraviolet (UV) spectroscopy, high-performance liquid chromatography (HPLC), and ultra-high-performance liquid chromatography (UHPLC). The comparative assessment of these techniques highlights the significance of advanced chromatographic methods, particularly UHPLC, for enhanced resolution and reduced analysis time. This review serves as a valuable resource for researchers and analysts in the pharmaceutical and biomedical fields, aiding in the selection of appropriate analytical methodologies for prucalopride determination.
Cite this article:
Mohit Sunil Pawar, Hetakshi Vilas Patil, Harshada Kailas Patil, Sejal Tukaram Patel, Amitkumar R. Dhankani, Mansi A. Dhankani, Sunil P. Pawar. A Compressive Review on Advances in Analytical Methodologies for Prucalopride. Asian Journal of Pharmaceutical Analysis. 2025; 15(3):229-5. doi: 10.52711/2231-5675.2025.00036
Cite(Electronic):
Mohit Sunil Pawar, Hetakshi Vilas Patil, Harshada Kailas Patil, Sejal Tukaram Patel, Amitkumar R. Dhankani, Mansi A. Dhankani, Sunil P. Pawar. A Compressive Review on Advances in Analytical Methodologies for Prucalopride. Asian Journal of Pharmaceutical Analysis. 2025; 15(3):229-5. doi: 10.52711/2231-5675.2025.00036 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2024-15-3-12
REFERENCES:
1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006; 130: 1480-1491.
2. Drossman DA, Dumitrascu DL. Rome III: New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis 2006; 15:237-241. 3. Sonnenberg A, Koch TR. Epidemiology of constipation in the United States. Dis Colon Rectum.1989; 32:1-8.
3. Sonnenberg A, Koch TR. Epidemiology of constipation in the United States. Dis Colon Rectum. 1989; 32:1-8.
4. Locke GR 3rd, Pemberton JH, Phillips SF. AGA technical review on constipation. American Gastroenterological Association. Gastroenterology. 2000; 119:1766-1778.
5. Müller-Lissner SA. Effect of wheat bran on weight of stool and gastrointestinal transit time: a meta-analysis. Br Med J (Clin Res Ed). 1988; 296:615-617.
6. Petticrew M, Rodgers M, Booth A. Effectiveness of laxatives in adults. Qual Health Care. 2001; 10:268-273.
7. Borum ML. Constipation: evaluation and management. Prim Care. 2001; 28:577-590.
8. Chaussade S, Minić M. Comparison of efficacy and safety of two doses of two different polyethylene glycol-based laxatives in the treatment of constipation. Aliment Pharmacol Ther. 2003; 17:165-172.
9. Bouhnik Y, Neut C, Raskine L, et al. Prospective, randomized, parallelgroup trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation. Aliment Pharmacol Ther. 2004; 19:889-899.
10. Attar A, Lémann M, Ferguson A, et al. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut 1999; 44:226-230.
11. Cleveland MV, Flavin DP, Ruben RA, Epstein RM, Clark GE. New polyethylene glycol laxative for treatment of constipation in adults: a randomized, double-blind, placebo-controlled study. South Med J. 2001; 94:478-481.
12. Corazziari E, Badiali D, Bazzocchi G, et al. long-term efficacy, safety, and tolerability of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut. 2000; 46: 522-526.
13. MiraLax polyethylene glycol 3550, NF powder for solution. Braintree Laboratories, Inc. Available from URL: http://www.drugs.com/cdi/ polyethylene-glycol-3350-powder-for-oral-solution.html (accessed 21 April 2016).
14. Ramkumar D, Rao SSC. Efficacy and safety of traditional medicaltherapies for chronic constipation: systematic review. Am J Gastroenterol. 2005; 100: 936-971.
15. Muller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005; 100:232-242.
16. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from URL: http://handbook.cochrane.org/ (accessed 21 April 2016).
17. Review Manager (Rev Man) [Computer program]. Version 5.0. The Nordic Cochrane Centre, The Cochrane Collaboration: Copenhagen, 2008. Available from URL: http://tech.cochrane.org/revman/download/ windows64 (accessed 21 April 2016).
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7:177-188.
19. Prins NH, Van Haselen JF, Lefebvre RA, et al. Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Br J Pharmacol. 1999; 127: 1431–1437
20. Briejer MR, Bosmans JP, Van Daele P, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol. 2001; 42: 71–83.
21. Priem E, Van Colen I, De Maeyer JH, et al. The facilitating effect of prucalopride on cholinergic neurotransmission in pig gastric circular muscle is regulated by phosphodiesterase 4. Neuropharmacology. 2012; 62: 2126–2135.
22. Bouras EP, Camilleri M, Burton DD, et al. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut. 1999; 44: 682–686.
23. Miner PB Jr, Camilleri M, Burton D, et al. Prucalopride induces high-amplitude propagating contractions in the colon of patients withchronic constipation: a randomized study. Neurogastroenterol Motil. 2016; 28: 1341–1348.
24. De Maeyer JH, Lefebvre RA and Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil. 2008; 20: 99–112.
25. Sanger, G.J. and Quigley, E.M.M. (2010) Constipation, IBS and the 5-HT4 receptor: what role for prucalopride? Clin Med Insights: Gastroenterology. 3: 21–33.
26. Bouras, E.P., Camilleri, M., Burton, D.D. and McKinzie, S. (1999) Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut.44: 682–686.
27. Bouras, E.P., Camilleri, M., Burton, D.D., Thomforde, G., McKinzie, S. and Zinsmeister, A.R. (2001) Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology. 120: 354–360.
28. Asim Tameez Ud Din, Ameer H. Khan, Hamza Bajwa, Muhammad Haisum Maqsood, Mustafa N. Malik, Clinical Efficacy and Safety Profile of Prucalopride in Chronic Idiopathic Constipation, Cureus Open Access. 11(4): e4382. DOI 10.7759/.
29. Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut. 1999; 44:682–686.
30. Emmanuel AV, Kamm MA, Roy AJ, Antonelli K. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut. 1998; 42:511–516.
31. Poen AC, Felt-Bersma RJ, Van Dongen PA, Meuwissen SG. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther. 1999; 13:1493–1497.
32. Emmanuel AV, Roy AJ, Nicholls TJ, Kamm MA. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther. 2002; 16:1347–1356.
33. Coremans G, Kerstens R, De Pauw M, Stevens M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion. 2003; 67:82–89.
34. Sloots CE, Poen AC, Kerstens R, et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther. 2002; 16:759–767.
35. Van de Velde V, Ausma J, Vandeplassche L. Pharmacokinetics of prucalopride (Resolor®) in man. Gut. 2008; 57: A282.
36. Investigator’s brochure on prucalopride. Movetis NV, Turnhout, Belgium.
37. Chauhan A, Mittu B, Chauhan P. Analytical method development and validation: a concise review. Journal of Analytical & Bioanalytical Techniques. 2015; 6(1): 1-5.
38. Bhavya K, Vishnumurthy KM, Rambabu D, Sumakanth M. ICH guidelines – “Q” series (quality guidelines) - A review. GSC Biological and Pharmaceutical Sciences. 2019; 6(3): 89-106.
39. Chawla G, Chaudhary KK. A review of HPLC technique covering its pharmaceutical, environmental, forensic, clinical and other applications. Int J Pharm Chem Anal. 2019; 6 (2): 27-39.
40. Wu N, Lippert JA, Lee ML. Practical aspects of ultrahigh pressure capillary liquid chromatography. Journal of Chromatography. 2001; 1: 9-11.
41. McNair HM, Miller JM. Basic Gas Chromatography. John Wiley & Sons, Inc.; 1998. p. 29-52.
42. Emery EM, Koerner WE. Dual column programmed temperature gas chromatography. Analytical Chemistry. 1962; 34:1196-8.
43. Pund, S.; Nalawade, S.; Rajurkar, V.; Jayatpal, S.; Deshmukh, N.; Tare, H. A Brief Review on Recent Advances in Reverse Phase HPLC. Multidiscip. Rev. 2024; 7(4): 2024072.
44. Food and Drug Administration. Final Report on Pharmaceutical cGMPs for the 21st Century – A Risk Based Approach. http://www.fda.gov/ cder/ gmp/ gmp 2004/ GMP_ final report 2004.htm. 2016
45. Dr. G. Abirami, Dr. T. Vetrichelvan, M. Raman, A Novel Validated Uplc Method for The Determination of Prucalopride Succinate in Solid Dosage Form, International Journal of Pharmaceutical Sciences. 2024; 2(12): 1035-1043.
46. Ms. Priya Chidrewar, Mr. Arun Sathe, Mrs. Prapti Desai, Development and Validation of a Stability-Indicating Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) Method for Assay of Prucalopride Drug Substance, EPRA International Journal of Research and Development (IJRD). 2023; 8(10).
47. Kumudini Rahul Pawar, Sanjay K Bais, Development and Validation Of HPLC-UV Method for Prucalopride Succinate Quantification in Biological Samples, Journal of Chemical Health Risks. JCHR. 2023; 13(4s): 771-779.
48. Chandanam Sreedhar, Manogna K, Sreenivasa Rao T, Akkamma HG, Bidyut Jyoti Krishna Boruah, New Analytical RP-HPLC Method Development and Validation for the Estimation of Prucalopride in Bulk and Pharmaceutical Dosage Form, RGUHS Journal of Pharmaceutical Sciences, RJPS. 2021; 11(3): 39-43.
49. A.C. Bhosale, V.C. Bhagat, V. V Kunjir, D.P. Kardile, R.V. Shete, Analytical Method Development and Validation of Prucalopride Succinate in Bulk and Formulation by UV-Visible Spectrophotometry, Research Journal of Pharmacy and Technology. 2021; 14(8).
50. Ashwini S. Chawathe, Purnima D. Hamrapurkar, Implementation of Quality by Design Approach for Analytical Method Development and Validation for Estimation of Prucalopride Succinate in the Bulk and Solid Dosage Form, International Journal of Pharmaceutical Quality Assuranc. 2020; 11(4).
51. G. Abirami, T. Vetrichelvan, M. Raman. Method development and validation of Prucalopride succinate in bulk and tablet dosage form by RP-HPLC method. Journal of Innovations in Pharmaceutical and Biological Sciences (JIPBS). 2020; 7(3): 7-12.
52. Vaibhavi N. Akhani, Mrs. Khushbu K. Patel, Ms. K. S. Patel, L.M. Prajapati and C. N. Patel, Development and Validation Of RP-HPLC Method for Estimation of Prucalopride Succinate in Pharmaceutical Dosage Form. World Journal of Pharmacy and Pharmaceutical Sciences. 2020; 9(6): 1112-1122.
53. Sangameshwar B. Kanthale, Sanjay S. Thonte, Sanjay S. Pekamwar, Debarshi K. Mahapatra. Development and Validation of a Stability Indicating RP-HPLC Method for the Determination of Prucalopride succinate in Bulk and Tablet. International Journal of Pharmaceutical Sciences and Drug Research. 2020; 12(2): 166-174